Since the astounding success of rituximab, the development of new antibodies for the treatment of lymphoma has become the main focus of drug development. One area of interest is in creating a fully humanized version of an anti-CD20 antibody. Putatively, humanization would lead to fewer infusion reactions, allowing for the more rapid infusion of the drug.
Also, a fully humanized molecule may better initiate antibody-dependent cellular cytotoxicity and enhance the efficacy of the drug. Finally, the humanized antibody may recognize a different epitope on CD20, theoretically overcoming one mechanism of rituximab resistancedownregulation or alteration of CD20. 3 In one trial of relapsed/refractory chronic lymphocytic leukemia (CLL), 12 of 26 patients (43%) responded to the humanized anti-CD20 antibody ofatumumab. 4 Ofatumumab and other humanized anti-CD20 antibodies are now in clinical trials targeting, in particular, patients with follicular lymphoma and chronic lymphocytic leukemia who are rituximab -refractory.
A variety of antigenic targets besides CD20 are now also being pursued.
Galiximab is an immunoglobulin (Ig)-G1 antibody that binds to CD80, a costimulatory molecule expressed on B cells that is involved in T-cell activation. 5 A phase I/II trial of galiximab in combination with rituximab in patients with rituximab -sensitive follicular lymphoma demonstrated an overall response rate of 66% (19% complete response (CR), 14%
unconfirmed (u) CR, and 33% partial response (PR)) in the group of patients treated at the highest dose level (500mg/m 2 ). 6 Co-administration of the two antibodies did not appear to affect the pharmacokinetics of either. An ongoing trial is studying rituximab with or without galiximab in patients with rituximab-sensitive follicular lymphoma. Another target is CD40, a member of the tumor necrosis factor receptor family that is expressed on B Other promising therapies continue to emerge beyond the realm of monoclonal antibodies. The following list is not exhaustive, but is merely a sampling of some of the more promising emerging agents.
Protein kinase C beta (PKCβ) is a serine/threonine kinase associated with poor outcome in DLBCL. 11, 12 Enzastaurin is an oral drug that selectively inhibits PKCβ. In a phase II study of 55 patients with relapsed/refractory DLBCL, three patients experienced a CR and eight patients remained free from progression for four cycles. 13 Although the overall response rate was not tremendously high, this was a heavily pre-treated group of patients and occasional dramatic responses were observed. The drug was also well tolerated, with grade III toxicities including fatigue, edema, headache, motor neuropathy (one patient), and thrombocytopenia, with no grade III or IV neutropenia. Due to the small-but real-CR rate, oral administration, and favorable toxicity profile, it is reasonable to study the drug further. An ongoing randomized phase III trial is examining the effect Hematological Cancer
of enzastaurin consolidation in patients with DLBCL and an International Prognostic Index (IPI) score of three or greater who achieve a CR/uCR after rituximab-CHOP. Perhaps introducing the drug in the up-front setting in patients with debulked disease will decrease relapses and improve survival.
Expression of B-cell lymphoma 2 (Bcl-2) protein is associated with chemotherapy resistance and decreased survival in B-cell malignancies.
The antisense oligonucleotide oblimersen, designed to downregulate Lenalidomide is commercially available for the treatment of myelodysplastic syndrome and multiple myeloma. There is also an increasing body of evidence to suggest that lenalidomide will be effective in lymphoid malignancies. In a study of 45 patients with CLL, 51% of whom were refractory to fludarabine, the overall response rate with lenalidomide was 47%, with 9% CR. 15 Such responses have been replicated in other trials. 16 In a phase I trial of lenalidomide in mantle cell lymphoma (MCL), five of six patients treated at the maximal tolerated dose of 20mg on days one to 21 of a 28-day cycle achieved responses, including one CR, one PR, and three minor responses. 17 A phase II trial in MCL is now ongoing. In a phase II trial of 50 patients with relapsed/ refractory aggressive B-cell NHL treated with lenalidomide 25mg by mouth during days one to 21 of a 28-day cycle, 14 patients (34%)
exhibited an objective response (five uCR and nine PR) and 12 had stable disease (SD) for a tumor-control rate of 63%. 18 Finally, in a study of 43 patients (27 evaluable) with relapsed/refractory indolent B-cell NHL, seven patients (26%) exhibited an objective response (two CR, one uCR, and four PR, and nine had SD for a tumor-control rate of 59%). 19 The primary toxicity of lenalidomide in these studies has been myelosuppression, although venous thromboembolic events remain a concern. Confirmatory trials of lenalidomide alone or in combination with other agents are being conducted in all of the histologies listed above.
T-cell lymphoma comprises a wide variety of diseases, which as a whole account for approximately 10-15% of all cases of NHL. In general, T-cell NHLs are less responsive to chemotherapy and have a poorer prognosis than B-cell NHL. Until recently, there was a paucity of new drug development for T-cell malignancies, but this has slowly yet steadily started to change.
One of the most promising emerging agents for the treatment of T-cell NHL is the novel folate antagonist pralatrexate (PXD008). Pralatrexate is a rationally designed drug that is a high-affinity substrate for the reduced folate carrier-1 (RFC-1). It provides effective active transport into many malignant cells, where it is polyglutamated by folylpolyglutamate synthetase (FPGS), with subsequent inhibition of dihydrofolate reductase. 20 The drug has been studied quite extensively in lung cancer, but its most impressive activity is in T-cell lymphoma.
A been tested in two trials of patients with refractory cutaneous T-cell lymphoma. 22 Dose ranges were 280, 560, and 980mg, all given weekly for 17 doses. In the lowest dose arm the response rate in mycosis fungoides was only 15%, but at the higher doses the overall response rate was 56%. Toxicity was mild and mostly limited to minor infections of the skin and upper respiratory tract, infusion reactions, and eczematous dermatitis. As predicted, transient depletion of CD4 cells was observed. Currently, a pivotal trial is under way to confirm these findings, but the preliminary data suggest that this agent would be useful in treating cutaneous T-cell lymphoma (CTCL).
Zanolimumab has also been studied in patients with relapsed/refractory peripheral T-cell lymphoma. Of 15 patients treated with zanolimumab 980mg weekly, two patients experienced uCR, two patients PR, and two patients had stable disease. 23 Four serious adverse events were attributed to the study drug, including febrile neutropenia, thrombocytopenia (an infusion-related reaction), and hyperthermia with hypotension. The This discussion covered only a few of the new agents in development for lymphoid malignancies. The greatest challenge moving forward, in addition to developing new agents, is incorporating the increasing number of effective therapies into a rational treatment regimen. Clearly, administering a multitude of antibodies and chemotherapeutic agents to every patient will not be feasible. Thus, new modalities such as gene expression profiling that help us to predict which tumors will respond to the various therapies will be critical. ■
